Astellas Gene Therapies dans l'actualité
Développement de médicaments génétiques
Tamtam a trouvé 15 articles récents sur Astellas Gene Therapies.
- A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
- Report details damage to sensory nerve cells with Pompe gene therapy in case
- Astellas retries XLMTM gene therapy after deaths
- Astellas Licenses Dyno Therapeutics’ AI-Designed AAV Capsid, Advancing Gene Delivery for Muscle Disorders
- Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement
- Astellas Takes Aim at XLMTM Again, Now with MyoAAV Capsid-Based Gene Therapy
- Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
- Astellas Gene Therapies to Close Biomanufacturing Facility, Affecting About 100 Employees
- In analysis of gene therapy deaths, Astellas points to underlying liver issues
- Staying the Course: New CEO, Same Focus for Astellas Gene Therapies
- Astellas, despite recent setbacks, opens $100M gene therapy plant
- Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina
- Fourth trial volunteer dies in Astellas gene therapy study
- Audentes Therapeutics Expands Mission, Becomes Astellas Gene Therapies
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Astellas Gene Therapies ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires